Liquidia (LQDA) Dropped, So What Is Behind The Sudden Shift?

Liquidia (LQDA) is under pressure after a U.S. District Court in Delaware found that its Yutrepia drug infringed two valid United Therapeutics patents, prompting a rapid selloff as investors reassessed legal and regulatory risks.

The legal ruling has hit Liquidia at a point where momentum had already cooled, with the share price falling around 57% over the past day and around 62% over 90 days. However, the 1-year total shareholder return remains positive at about 37%, and the 5-year total shareholder return is more than 10 times the starting level. This combination points to a long period that has rewarded holders, followed by a sharp recent reset as legal risks are repriced.

Look beyond Liquidia's legal setback and examine a curated group of biopharma peers facing their own inflection points with the 19 high quality undiscovered gems.

After a drop this steep, the real puzzle is whether Liquidia has already given back most of its long run-up, or whether the recent reset still leaves meaningful upside on the table once you run the numbers.

Most Popular Narrative: 77% Undervalued

On the most followed narrative, Liquidia’s fair value sits at $130 against a last close of $30.26. This creates a wide gap that turns every legal and commercial swing into a big valuation debate.

Expanding use of inhaled treprostinil across broader fibrotic and inflammatory lung conditions such as IPF, PPF and PH-COPD is creating a multi-indication franchise opportunity that can meaningfully increase Liquidia’s addressable market and long term revenue base.

See why 2 investors see Liquidia as 77% undervalued.

Result: Fair Value of $130 (UNDERVALUED)

Still, the bullish Liquidia story hinges on unresolved patent disputes and heavy reliance on YUTREPIA. An adverse ruling or slower adoption could quickly flip the script.

Find out about the key risks to this Liquidia narrative.

Next Steps

Legal risk and upside potential now sit side by side for Liquidia, so move quickly, review the data firsthand and weigh the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Liquidia?

You have seen how quickly the story can change for Liquidia, so do not stop here. Broaden your watchlist with focused stock ideas built from hard numbers.

• Target potential value rebounds by scanning companies that combine quality fundamentals with attractive pricing through the 31 high quality undervalued stocks.
• Prioritize resilience by filtering for businesses with robust finances using the list of solid balance sheet and fundamentals (25 results).
• Lean into consistency by reviewing companies that score well on stability and risk using the 31 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com